Understanding Type 1 Galactosemia

a rare genetic disease that can be life-threatening for newborns and can cause lifelong cognitive, neurological, speech, and fertility complications.¹





Galactosemia Foundation Linked for Life

Type 1 galactosemia is a rare genetic disease that can be life-threatening for newborns and can cause lifelong cognitive, neurological, speech, and fertility complications.¹ Type 1 galactosemia is **caused by mutations in the** *GALT* **gene**.² The *GALT* **gene**'s job is to tell the body's cells how to make the galactose-1-phosphate uridylyltransferase enzyme, or the **GALT enzyme**.^{1,2}

- \cdot Type 1 galactosemia includes classic, clinical variant, and Duarte galactosemia¹
- Symptoms of Type 1 galactosemia typically occur in classic and clinical variant galactosemia¹

Why do we need GALT enzymes?

••	
\sim	
	

GALT enzymes help the body process galactose, a sugar that is naturally produced in the body and found in dairy, breast milk, and other foods.^{2.3}

Genetic mutations in the *GALT* gene means the body is not able to produce enough functional GALT enzyme.^{1,2}



Without the GALT enzyme, a buildup of galactose occurs, which results in the accumulation of additional substances including galactose-1

phosphate (Gal-1P) and galactitol. Too much galactose, Gal-1P, and galactitol in the body is toxic and may contribute to lifelong complications.^{2,3}

The risk and severity of galactosemia depends on the types of mutations in the *GALT* gene and their resulting level of GALT enzyme activity.¹

Restricting galactose in people with galactosemia is critical, but not enough.

The current standard of care for galactosemia is a galactose-restricted diet.³ If galactose is removed from a newborn's diet quickly, severe symptoms, like liver failure and death may be avoided.²

However, **the body produces endogenous galactose**, which means it produces galactose naturally, no matter what foods are eaten.¹ So, even when the recommended diet is strictly followed, lifelong complications can still occur.²

Lifelong Complications

As children with Type 1 galactosemia grow, **the buildup of galactose, Gal-1P and galactitol continues**, which can contribute to lifelong complications.²³



Cognitive and motor delays (49.7%)⁴







Language delay (78.0%), and language and speech disorders (66.4%)⁴



Primary ovarian insufficiency (79.7%), which often requires hormone replacement therapy (83.5%)⁴ and may lead to difficulty in getting pregnant



Poor growth⁵ and delayed puberty for girls **(48.5%)** and boys **(4.8%)**⁴



Movement and coordination challenges (27.0%)⁴




Cataracts (25.8%)⁴

The numbers above represent the percentage of people with Type I galactosemia who reported symptoms in a retropsective obervational study of 509 participants.⁴

How is a child born with galactosemia?

Galactosemia is an autosomal recessive disease. This means the parents of a child with galactosemia are usually carriers of the genetic mutation. Carriers have one dominant working gene and one recessive non-working gene with a mutation. Carriers do not experience symptoms of the disease. A child is born with galactosemia when they inherit two copies of the gene mutation.¹²



Newborn Screening

Because galactosemia is life-threatening, newborn screening for Type 1 galactosemia is conducted in every state in the United States and several other countries.

Newborn screening is usually done within 48 hours of birth; however, the results may not be available for several days. Since many parents are unaware that they are carriers, a child may be fed breastmilk or infant formula containing galactose, which can cause life-threatening complications.



Because diet is not enough, researchers are developing potential new treatments.

Talk with your doctor about ways to get involved in galactosemia research. You can also visit **Galactosemia.org** or **JaguarGeneTherapy.com** to learn more.

References 1. Berry GT. Classic Galactosemia and Clinical Variant Galactosemia. 2000 Feb 4 [Updated 2021 Mar 11]. In Adam MP, Ardinger HH, Pagon RA, et al., editors GeneReviews". Seattle (WA): University of Washington. Seattle: 1993-3021. https://www.ncbi.nlm.nih.gov/books/NBK/1518/. Accessed July 30, 2021. 2. Galactosemia. NORD (National Organization for Rare Disorders). https://rarediseases.org/rare-diseases/galactosemia/. Published May 2019. Accessed July 1, 2021. 3. Welling L, Bernstein LE, Berry GT, et al. International clinical guideline for the management of classical galactosemia: toignosis, treatment, and follow-up. J Inherit Metab Dis. 2017;40:171-176. https://onlinelibrary.wiley.com/doi/full/10.1007/s10545-016-9990-5. 4. Rubio-Gozalbo ME, Haskovic M, Bosch AM, et al. The natural history of classic galactosemia: lessons from the GalNet registry. Orphanet J Rare Dis. 2019; 14:86. https://doi.org/10.1186/ s13023-019-1047-z. 5. Panis B, Gerver WJM, Rubio-Gozalbo ME. Growth in treated classical galactosemia patients. Eur J Pediatr. 2007;166:443-446.